- Installation of FiberVision® molecular
combing platform at Necker-Enfants malades Hospital
- Development of new genetic tests to
enrich Genomic Vision's portfolio in new indications
Regulatory News:
Genomic Vision (Paris:GV) a French molecular diagnostics company
specializing in the development of diagnostic tests for genetic
diseases and cancers based on molecular combing technology, today
announces the signing of a strategic partnership with the
University-Hospital Institute (IHU) Imagine, the largest European
genetic research and care cluster. The FiberVision® molecular
combing platform has been installed by the Genomic Vision team at
the Institute’s campus of the Necker-Enfants Malades Hospital,
which cares for 40,000 patients each year, more than half of which
have genetic diseases.
This public-private partnership fits with Genomic Vision's
strategy for the university hospital market: to form strategic
collaborations with Centers of Excellence in genetic diseases and
oncogenetics in order to make its innovative technology widely
available in medical and academic settings.
The purpose of this collaboration with the IHU Imagine is to
identify pathologies caused by complex structural variations that
are difficult to identify with existing methods, thus contributing
to the creation of new genetic tests that benefit patients and will
enrich the Genomic Vision’s product portfolio.
"In order to cure a genetic disease, it is first necessary to
identify the genes responsible, characterize their mutations and
understand the disruptions they generate. This is particularly
difficult in the case of large rearrangements within the genome,
which are almost undetectable with conventional technologies.
Genomic Vision's molecular combing will considerably reinforce our
ability to explore those mutations that give rise to numerous
pathologies, in order to treat them better," comments Professor
Arnold Munnich, M.D., Founder and Director of the Department of
Genetics at Necker-Enfants malades Hospital.
Aaron Bensimon, Ph.D., Co-Founder and Chairman of the Board
of Genomic Vision, concludes: "The installation of our
FiberVision® molecular combing platform in the heart of the largest
European genetic research and care cluster is an important
advancement for Genomic Vision. This partnership allows us to share
our technological know-how in molecular diagnostics with the
researchers at the Imagine Institute and create synergies for
developing new diagnostic tests that will benefit many patients.
The tests arising from this collaboration may create important
growth engines for Genomic Vision in new indications with strong
potential, while complementing our ongoing developments."
Upcoming financial publication
- Annual Revenue for 2015, Monday,
January 18, 2016* (after trading)
* indicative date, which may be subject to
change
ABOUT GENOMIC VISIONFounded in 2004, Genomic Vision is a
molecular diagnostics company that specializes in the development
of diagnostic tests for genetic diseases and cancers based on
molecular combing. Using this innovative technology that allows the
direct visualization of individual DNA molecules, Genomic Vision
detects quantitative and qualitative variations in the genome that
are at the origin of numerous serious pathologies. The Company is
developing a solid portfolio of tests that initially target breast
and colon cancers. Since 2013, the Company has marketed the
CombHelix FSHD test for identifying facioscapulohumeral dystrophy
(FSHD), a myopathy that is difficult to detect. It is marketed in
the United States through a strategic alliance with Quest
Diagnostics, the American leader in diagnostic laboratory tests,
and in France directly by the Company. Genomic Vision has been
listed on Compartment C of Euronext Paris since April 2014.
ABOUT MOLECULAR COMBINGDNA molecular combing technology
significantly improves the structural and functional analysis of
DNA molecules. DNA fibers are stretched over glass slides, as if
"combed", and uniformly aligned over the entire surface. It is then
possible to identify genetic anomalies by locating specific genes
or sequences in the patient's genome using genetic markers, a
technique developed by Genomic Vision and patented under the name
Genomic Morse Code. This exploration of the entire genome at high
resolution via a simple analysis enables the direct visualization
of genetic anomalies that are undetectable by other
technologies.For further information, please go to:
www.genomicvision.com
●●●
ABOUT THE IMAGINE INSTITUTE
The mission of the Imagine Institute, the leading European
cluster in genetic disease research, care and teaching, is to
understand and cure these diseases. Approved as a
University-Hospital Institute in 2011, Imagine was founded by
AP-HP, Paris Descartes University, Inserm, the Hospitals of
Paris-Hospitals of France Foundation, Paris City Hall and
AFM-Telethon.
The Institute gathers 850 of the best doctors, researchers and
health care staff in a synergy-creating architecture. It is this
unprecedented continuum of expertise, associated with the proximity
of patients, that allows Imagine to accelerate discoveries and
their applications to benefit patients. www.institutimagine.org
About AP-HP:
AP-HP is an internationally recognized hospital center of
European dimension. Its 39 hospitals receive 7 million patients
each year: in consultations, the emergency department, scheduled
hospitalizations and home visits.
It ensures a public health service for everyone, 24/7, both as a
duty and source of pride. AP-HP is the largest employer of
Ile-de-France: 95,000 individuals – doctors, researchers,
paramedics, administrative staff and laborers – work there.
www.aphp.fr
About Inserm:
Created in 1964, the French Institute of Health and Medical
Research (Institut National de la Santé et de la Recherche
Médicale, Inserm) is a public scientific and technical institution,
jointly managed by the French Ministry of Higher Education and
Research and the French Ministry of Health. Its researchers are
dedicated to the study of all diseases, from the most common to the
rarest, through their work in biological, medical and community
health research. Inserm celebrated its 50th anniversary in 2014.
www.inserm.fr
About the Paris Descartes University:
Paris Descartes University, the university of health and human
sciences of Paris. With its nine Training and Research Units (UFR)
and its Institute of Technology (IUT), the Paris Descartes
University covers the entire range of human and health sciences.
Its health cluster, the only university in Ile-de-France that
includes medicine, pharmacy, dentistry and midwifery, is
internationally recognized for the quality of its training and the
excellence of its research.
WARNING
This news release contains forward-looking statements concerning
Genomic Vision and its activities. Such forward-looking statements
are based on assumptions that Genomic Vision considers to be
reasonable. However, no guarantee can be given concerning the
achievement of the expectations expressed in these forward-looking
statements, which are subject to risks, including those described
in the prospectus approved by the AMF under number 14-087, dated 19
March 2014, and to developments in the economic environment,
financial markets and the markets in which Genomic Vision is
present. The forward-looking statements that appear in this press
release are also subject to risks unknown to Genomic Vision or that
Genomic Vision does not consider to be significant at this time.
The occurrence of any or all of these risks could lead to a
significant difference between the actual results, financial
conditions, performances or achievements of Genomic Vision and the
results, financial conditions, performances or achievements
expressed in these forward-looking statements.
This press release and the information it contains do not
constitute, and cannot be interpreted as an offer or invitation for
sale or subscription, or as a solicitation of any order or offer to
buy or subscribe Genomic Vision shares in any country. The
distribution of this press release in certain countries may
constitute a breach of applicable law. Persons who come into
possession of this press release should inform themselves of and
observe any restrictions.
Member of the CAC® Mid & Small,
CAC® All-Tradable and EnterNext© PEA-PME
150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151203005964/en/
Genomic VisionAaron BensimonCo-Founder, Chairman of the
Board of DirectorsTel.: +33 (0)1 49 08 07
50investisseurs@genomicvision.comorImagine
InstituteBéatrice
Parinello-Fromentbeatriceparrinello@bpfconseil.comTel.: +33 (0)6 63
72 16 06Pauline
Rodrigue-Moriconipauline.rodrigue@institutimagine.orgTel.: +33 (0)6
77 23 71 19orNewCapInvestor Relations & Strategic
CommunicationsDušan Orešanský / Emmanuel HuynhTel.: +33 (0)1 44 71
94 92gv@newcap.euorLHAInvestor Relations USAnne Marie
Fields, SVPTel.: 212-838-3777afields@lhai.com
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024